Sign in to confirm you’re not a bot
This helps protect our community. Learn more

InMed Pharmaceuticals at Edison Open House Global Healthcare Conference 2022

InMed Pharmaceuticals
76 subscribers
<__slot-el>
<__slot-el>
185 views 3 years ago
InMed's CEO, Eric A. Adams, joins the 2022 Edison Open House Global Healthcare Conference on January 25th. In this discussion, Eric talks about the untapped potential of the rare cannabinoid market and how the company is well-positioned to take a lead in this emerging market. He also talks about the recent launch of rare cannabinoid, cannabicitran or CBT, as a raw ingredient for the health and wellness industry, the company's Phase 2 program of rare cannabinoid cannabinol as a potential treatment for epidermolysis bullosa and the library of new patentable cannabinoid analogs being developed. With the recent acquisition of BayMedica, InMed's rare cannabinoid programs now span a broad range of specialties - from cannabinoid manufacturing to pharmaceutical development to commercial sales of rare cannabinoids as raw ingredients for the health and wellness sector. The acquisition has also bolstered the team, adding significant cannabinoid knowledge and expertise in biosynthesis and synthetic biology and chemistry. ...more
...more
InMed Pharmaceuticals at Edison Open House Global Healthcare Conference 2022
6Likes
185Views
2022Jan 26
InMed's CEO, Eric A. Adams, joins the 2022 Edison Open House Global Healthcare Conference on January 25th. In this discussion, Eric talks about the untapped potential of the rare cannabinoid market and how the company is well-positioned to take a lead in this emerging market. He also talks about the recent launch of rare cannabinoid, cannabicitran or CBT, as a raw ingredient for the health and wellness industry, the company's Phase 2 program of rare cannabinoid cannabinol as a potential treatment for epidermolysis bullosa and the library of new patentable cannabinoid analogs being developed. With the recent acquisition of BayMedica, InMed's rare cannabinoid programs now span a broad range of specialties - from cannabinoid manufacturing to pharmaceutical development to commercial sales of rare cannabinoids as raw ingredients for the health and wellness sector. The acquisition has also bolstered the team, adding significant cannabinoid knowledge and expertise in biosynthesis and synthetic biology and chemistry.

Follow along using the transcript.

InMed Pharmaceuticals

76 subscribers